Abstract

The anti-human immunoglobulin E (IgE) monoclonal antibody, omalizumab (Xolair®, Genentech, South San Francisco, CA), is effective in the treatment of poorly controlled moderate to severe allergic asthma and chronic idiopathic urticaria. It acts by specifically binding to the constant domain (Ce3) of free human IgE in the blood and interstitial fluid. Although efficacious, use of omalizumab is limited due to restrictions on patient weight and pre-existing IgE levels, and frequent dosing (q2–4 weeks). A vaccine inducing anti-IgE antibodies has the potential for similar clinical benefits with less frequent dosing and relatively lower cost of goods. We developed a vaccine containing two IgE peptide-conjugates targeting the Ce3 domain of human IgE. As part of preclinical evaluation of the vaccine to optimize formulation and dose prior to initiating clinical studies, we evaluated the vaccine in non-human primates, and demonstrate the induction of anti-peptide antibodies that can bind to conformationally intact human IgE and are capable, at least in some animals, of substantial lowering circulating IgE levels.

Introduction

The incidence of IgE-mediated allergic conditions, including allergic asthma and rhinitis, has significantly increased over the last few decades, resulting in significant morbidity and mortality and associated costs [1]. In the US, the Center for Disease Control and Prevention reported a 73.9% increase in self-reported asthma during the period from 1980 to 1996 [2–4].

Despite the availability of multiple treatment modalities, including pharmacotherapy to treat symptoms and immunotherapy to address underlying immunological defects, there remains a significant unmet medical need for new therapeutic approaches to treat and potentially modify allergic diseases [5].

Elevated levels of immunoglobulin E (IgE) are characteristic of allergic diseases [6, 7]. Allergen-specific IgE binds to the high affinity receptor (FcεRI) found on the surface of mast cells, basophils, and eosinophils; cross-linking of adjacent bound IgE molecules by environmental allergen leads to the release of histamine and other mediators of allergic disease [8]. IgE can also bind to low affinity CD23 receptors on B cells, providing a negative regulatory signal for IgE production [7].
Immunoglobulin E (IgE) has long been used as a diagnostic biomarker, and more recently it has become a therapeutic target. Omalizumab (Xolair®, Genentech) is a humanized anti-IgE monoclonal antibody that directly targets free IgE, preventing it from binding to FceRI. Omalizumab was originally approved for the treatment of moderate to severe allergic asthma in patients who are not well controlled by inhaled corticosteroids [8–11]. It has more recently been approved for the treatment of chronic idiopathic urticaria, which is typically not allergen-induced but involves IgG nonetheless, at least in some patients [12, 13]. Off-label use of omalizumab, such as for allergic rhinitis and food allergies, has also been evaluated in clinical studies [5, 14–16]. When used at recommended doses, omalizumab results in a rapid, dramatic (>95%), and sustained decline in levels of free serum IgE that is associated with clinical benefit [17]. Dosing of omalizumab for allergic asthma is weight based (mg/kg) with the prescribed dose depending on the level of total serum IgE (IU/mL) at initiation of treatment. As such, drug use is limited to patients under a certain weight and/or with baseline IgE under a certain level [18, 19]. Prescribing is further restricted due to high cost [20] and frequency of dosing (every 2–4 weeks) and the need for the subcutaneous injection to be performed in the clinic due to rare anaphylactic reactions [21]. For chronic idiopathic urticaria, absolute doses of omalizumab are prescribed, but the same limitations exist as for asthma [22].

In theory, an IgE targeting vaccine could provide clinical benefits similar to omalizumab except with less frequent dosing and relatively lower cost of goods [23, 24]. It is not desirable to use whole IgE as the vaccine antigen since antibodies that can bind to receptor-bound IgE could result in cross-linking and anaphylaxis. A 76-amino acid peptide corresponding to the region at the border of Cε2–Cε3 that binds to FceRI has been shown to block in vivo passive sensitization of human skin mast cells and in vitro sensitization of human basophil granulocytes with human IgE antibodies [25]. A fusion protein consisting of the Cε2–Cε3 domain of rat IgE fused to carrier protein glutathione-S-transferase resulted in IgE lowering in vaccinated rats, as well as reduction in allergen sensitivity [26]. While there was no evidence of cross-linking receptor-bound IgE in these studies, there remains a potential risk for auto-reactive T cells with the use of longer peptides. Shorter peptides can reduce this risk, however used alone peptides are poorly immunogenic and, therefore, unlikely to induce the required titers and functionality of anti-peptide antibodies. The use of a carrier protein to provide structural support of the correct conformation and T-helper epitopes is required for adequate immunogenicity of self-peptide based vaccines and for the induction of antibodies that can cross-react to the intact target molecule [27, 28]. One approach is to make recombinant proteins that include the desired peptide sequence, for example, combining the homologous Cε3 sequences with heterologous and evolutionary distant Cε2 and Cε4 domains [29, 30], or cloning the Cε3 epitopes into a gene for a foreign protein, such as green fluorescent protein [31]. Another approach is to conjugate the peptides to a carrier molecule, as has been demonstrated using one or more Cε3-derived peptides of various lengths conjugated to a carrier such as Keyhole limpet hemocyanin (KLH), surface antigen of the hepatitis B virus (HBsAg), or a purified protein derivative of tuberculin [32–34]. While most studies on anti-IgE vaccines have been conducted in rodents, IgE lowering following immunization with a peptide conjugate vaccine or a chimeric protein vaccine has also been demonstrated in dogs [34, 35].

A number of IgE peptide antigens were rationally designed, using structural information for IgE and its interaction with the high affinity FceRI receptor such that the anti-IgE antibodies induced by the vaccine will bind free IgE, but not interact with IgE bound to cell surface receptors, thus avoid triggering the release of inflammatory mediators through IgE receptor cross linking [36].

Through extensive screening in mice two peptides were selected for further development. Screening involved immunization of mice with peptides conjugated to a virus-like particle (VLP) that is derived from QB bacteriophage (Qb-VLP) then ex vivo assessment of anti-sera by ELISA for high titers of antibodies recognizing human IgE and in vivo functional assessment of rate of clearance of human IgE after bolus administration to mice. Selected peptides were also screened to ensure that induced antibodies do not induce degranulation of FceRI receptor-expressing cells through binding to receptor bound IgE and that they do not induce a T cell responses. The two selected peptides, labeled peptide P and peptide Y, are derived from different loops of the Cε3 domain of IgE. Peptide Y corresponds to the epitope recognized by omalizumab while peptide P targets a different loop on IgE Cε3 [36]. Mice immunized with the two conjugates admixed in equal proportions and adjuvanted with aluminum hydroxide (alum) produce high levels of IgE-specific antibody that can bind to free but not receptor-bound human IgE and enhances the rate of clearance of human IgE after a bolus injection into immunized mice [36, 37]. In rodent species, the human vaccine cannot be used to assess function directly due to lack of homology, however, species-specific mimetic vaccines containing murine homologues of the Y and P peptides conjugated to Qb-VLP was shown to be capable of breaking B cell tolerance and induce anti-IgE antibodies than can lower serum IgE in a murine allergy model [36, 37]. Similarly, peptides derived from Cε3 domain of canine IgE has been shown to induce anti-IgE and have therapeutic benefit in multiple dog allergy models [38, 39].
In the current study, we evaluated the anti-IgE vaccine in non-human primates (NHP) for immunogenicity and function (lowering of circulating IgE). Cynomolagus monkey (*Macaca fascicularis*) was selected since there is a ~85% sequence homology between human and cynomolgus IgE constant region with a 100% homology for the P peptide and only single amino acid difference for the Y peptide [40].

Materials and Methods

**IgE peptide: VLP conjugates**

Qb-VLP was made by Pfizer using *Escherichia coli* K12 strain RB791 transfected with the plasmid pTac-nSDQb-mut containing the coding region of the Qb bacteriophage protein monomer (NCBI GenBank Acc. No. M99039; nucleotide 46–444). Cells were lysed by homogenization in the presence of Triton X-100 (Sigma–Aldrich, San Diego, CA). Cell debris was removed by centrifugation. Qb-VLP was purified using a series of chromatography steps: Fractogel TMAE (EMD Millipore, Darmstadt, Germany), Ceramic Hydroxyapatite Type II (Biorad, Hercules, CA), Phenyl Sepharose (GE Healthcare, Pittsburg, PA), and Sepharose CL-4B (GE Healthcare). After the final column, the pooled fractions were concentrated to 3 mg/mL using a Pall Ultrafiltration system equipped with a 100 kD Pellicon 2 Biomax V-screen PES cartridge. Samples were frozen at −80°C until further use.

Peptides P and Y were sourced from Chinese Peptide Company (CPC, Hangzhou, China). The sequence of peptide P is ADSNPRGVSAYLSRPSPGGC and the sequence of peptide Y is QCRVTHPHLRALMRS. Cysteines were added to each peptide sequence to allow conjugation through the sulfhydryl group of the added cysteine using the bifunctional linker, Succinimidyl-6-[[(maleimido)propionamido]hexanoate (SMPH; Sigma–Aldrich).

Qb-VLP conjugates were prepared by a two-step process which first involved activating the Qb-VLP with SMPH and secondly, conjugating with peptide. A 10× molar excess (for peptide P) or 4.25× molar excess (for peptide Y) SMPH in DMSO (Sigma–Aldrich) was added to 100 mg of Qb-VLP at 3 mg/mL in 20 mM sodium phosphate, 150 mM NaCl, pH 7.2. Activation proceeded at 15°C for 5 h with continuous mixing. After 5 h, the activated Qb-VLP was purified and buffer exchanged into 100 mM sodium phosphate, 300 mM NaCl, pH 6.8 by ultrafiltration/diafiltration (UF/DF) using a Sartorius Slice UF system installed with a Biomax 300 kD membrane. The purified activated Qb-VLP was diluted to 1 mg/mL with 100 mM sodium phosphate, 300 mM NaCl, pH 6.8, and peptide was added at a 7× molar excess. Conjugation proceeded at 15°C for 1.5 h with continuous mixing. After 1.5 h, the conjugated Qb-VLP was purified and buffer exchanged into 100 mM sodium phosphate, 200 mM NaCl, pH 7.2 by UF/DF using a Sartorius Slice UF system installed with a Biomax 300 kD membrane. Sucrose at 140 mg/mL and PS20 at 0.2 mg/mL were added to the purified peptide-Qb-VLP conjugates. The concentration was adjusted to 2.5 mg/mL and the conjugates were frozen at −80°C until further use.

**Adjuvants**

Aluminum hydroxide was obtained in the form of Alhydrogel “85+” (Brenntag Biosector, Frederikssund, Denmark) and is hereafter referred to as alum, with doses indicating amount of Al³⁺.

CpG ODN (CpG) (B-Class with sequence of 5’ TCG TCG TTT TTC GGT GCT TTT 3’) was synthesized by Avecia (Milford, MA) with a nuclease-resistant phosphorothioate backbone) as described previously [41].

**Animal model and immunization**

Cynomolgus monkeys (CiToxLAB., Montreal, QC) (mixed female and male; n = 6 to 8/group) aged between 2 and 5 years were used in the studies. Circulating IgE titer in study animals ranged from 10 (lower limit of quantification for the assay) to 3141 U/mL at study start. Animals were randomized into groups with group Geomean titers (GMT) of circulating IgE ranging from 52 to 126 U/mL. Monkeys were immunized as indicated on figure legends with P peptide and/or Y peptide conjugated to Qb-VLP (P-Qb and Y-Qb, respectively) with CpG and/or alum. Doses of antigen and adjuvants are defined in figure legends. All vaccine formulations were made up to a total volume of 1.0 mL with PBS and administered by intramuscular (IM) injection in the left quadriceps muscle. Animals were bled at predetermined intervals (weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 22, 26, and 28) by saphenous vein puncture and plasma/serum used for quantitation of antibody specific to the peptides, whole IgE, or the C3C4 portion of human IgE. In some studies, plasma/serum was also used for quantification of total IgE titer. All procedures performed on animals in this study were in accordance with regulations and guidelines reviewed and approved by the Pfizer Institutional Animal Care and Use Committee and were conducted in facilities fully accredited by AAALAC International.

**Detection of vaccine-specific antibody titers**

Antibody titers against the Y and P peptides, C3C4 domain, or whole human IgE, and the Qb-VLP carrier were measured by enzyme-linked immunosorbent assay (ELISA) using plasma or serum samples from individual animals. MaxiSorp 384-well plates (Fisher Scientific, Ottawa, ON, Canada) coated (12 μL/mL) with whole human IgE (7.5 μg/mL, Abbiotec, San Diego, CA), Qb-VLP (3 μg/
mL), Y or P peptides conjugated to KLH (1 or 2 μg/mL, respectively) were used for the detection of anti-IgE, anti-Qb, anti-Y, and anti-P titers, respectively. KLH was used for conjugation of peptides used in the ELISA in order to eliminate detection of any anti-carrier antibodies. Reacti-Bind™ Streptavidin HBC Clear 384-Well Plates (Fisher Scientific) coated (12 μL/mL) with biotinylated human C3C4 (1.5 μg/mL, Pfizer, Sandwich, UK) were used to detect anti-C3C4 titers. Selected samples were similarly tested on plates coated with cynomolgus C2C4 to compare anti-human and anti-cynomolgus antibody responses. Coated plates were incubated overnight at 4°C, except for plates coated with human C3C4 or cynomolgus C2C4 which were incubated for 1 h at room temperature. Following incubation, plates were aspirated and washed with PBS (for C3C4 or peptides) or PBS containing 0.05% Tween 20 (for whole IgE or Qb) and blocked 10% bovine calf serum (BCS; Hyclone, Logan, UT) for 1 h at room temperature. Samples were serially diluted in dilution buffer (10% BCS in DPBS) and added to the blocked and washed plates (12 μL/well). Plates were incubated at room temperature for 1 h on a shaker. The plates were washed again with PBS-0.05% Tween 20 and then incubated with goat anti-human IgG-horse radish peroxidase (HRP) (Southern Biotech, Birmingham, AL) diluted with dilution buffer (10% BCS in DPBS) for 1 h at room temperature. The plates were then washed again and incubated with Tetramethylbenzidine (TMB) substrate (Mandel Scientific, Guelph, ON) in the dark for 30 min at room temperature. The reaction was stopped by addition of 25 μL/well of 4N sulfuric acid (Fisher Scientific) and read at 450 nm using automated plate reader. Titers were defined as the highest serum dilution that resulted in an absorbance value (OD 450) two times greater than that of the diluent control. Group values were expressed as GMT ± 95% confidence interval (CI).

Except in cases where anti-IgE antibodies were detected with various coating reagents (Y, P, C2C4, C3C4, whole IgE) for comparison purposes, C3C4 was selected for routine detection of anti-IgE since it gave similar titers to those when plates were coated with whole human IgE.

Quantification of plasma/serum IgE level

The levels of circulating IgE in individual plasma or serum samples were quantified using the Monkey IgE ELISA kit (Alpha Diagnostic International, San Antonio, TX) as per manufacturer’s instructions. The sample OD was determined at wavelength 450 nm with OD subtraction at 630 nm using a SPECTRAMax Plus Microplate Spectrophotometer. The pre-existing endogenous IgE levels were measured in all animals at start of vaccination and the reduction in serum IgE is presented for individual animals as percent change in circulating IgE from baseline.

Anti-IgE antibody avidity

Antibody avidity was determined by competition ELISA as previously described [42]. In brief, serum or plasma samples previously determined to contain anti-IgE antibody were diluted in 10% BCS in DPBS to achieve absorbance values of approximately 1.0 at 450 nm. Human IgE (Abbiotec) was serially diluted twofold using the same buffer starting at two-times the highest desired concentration. Equal volumes of diluted serum/plasma sample or the diluent (10% BCS in DPBS) and IgE were incubated for 1 h at room temperature and then added to human IgE coated plates. HRP-labeled mouse anti-human IgG (Southern Biotech) followed by TMB substrate (Mandel Scientific) were used for the detection of antibody binding. OD readings at 450 nm were plotted against the molar concentration of IgE and the 50% inhibition (IC50) was extrapolated for each sample tested. Using the competition ELISA whereby IC50 was determined at equilibrium, the IC50 value equates to Kd [43].

Anti-IgE antibody specificity (competition)

Antibody specificity was determined using the same method as for avidity with the exception of using additional inhibitors; i.e., human IgG, IgM, IgA (Southern Biotech), and C3C4. For this assay, an equal volume of serially diluted inhibitor and diluted serum/plasma or the diluent (10% BCS in DPBS) were added directly to MaxiSorp 384-well plates coated with human IgE (7.5 μg/mL, 12 μL/well). The concentration ranges of the inhibitors were from 2.5 to 158 nM. Omalizumab (1 ng/mL, Genentech, South San Francisco, CA) was used as a positive control and the concentration ranges of the inhibitors for Omalizumab were from 0.2 to 13.1 nM. The Kd value was defined as amount of inhibitor required to achieve 50% inhibition of binding of anti-IgE antibody present in plasma/serum to human IgE.

Statistical analysis

Data were analyzed using GraphPad Prism (GraphPad Software, San Diego, CA). Statistical significance of the difference between two groups was calculated by Student’s 2-tailed t-test and between three or more groups by one-way or two-way ANOVA followed by post hoc analysis using either Dunn’s or Tukey’s multiple comparison tests. Differences were considered to be not significant with p > 0.05.

Results

Immunogenicity of Y-Qb

Y-Qb adjuvanted with alum and CpG was tested at different doses in cynomolgus monkeys for immunogenicity and the ability to decrease circulating IgE levels. Using plates coated
with human C3C4, it was found that a small number of monkeys (6%) had a low level of pre-existing anti-IgE (titers between 100 and 500), however, these pre-existing titers did not appear to interfere with vaccine immunogenicity and all animals showed an increase in anti-IgE titers post vaccination relative to baseline (Fig. 1). Only low levels of anti-IgE titers (<860 GMT at 4 weeks) were observed following the first vaccine administration at all dose levels tested, but these were substantially increased with each vaccine boost. No difference in the kinetics or the magnitude of the anti-IgE titers were observed between the different antigen dose levels of Y-Qb tested (Fig. 1A). Similar kinetics and magnitude antibody titers were obtained with selected samples tested on plates coated with human C3C4 and cynomolgus monkey C2C4, with a correlation value of $R^2 = 0.98$ (data not shown).

The avidity of antibodies following four administrations of Y-Qb at 45 and 900 µg (week 26) was tested and there was no antigen dose effect on the quality of the antibody response over this 20-fold antigen dose range (Fig. 1C).

Figure 1. Anti-C3C4 antibody titer and avidity in monkeys using Y-Qb alone or Y-Qb + P-Qb as antigen. Cynomolgus monkeys ($n = 8$/group) were immunized by IM injection on weeks 0, 4, 8, and 24 with either Y-Qb alone at 45, 100, 450, or 900 µg or with a mix Y-Qb and P-Qb (450 µg each) using alum (800 µg) and CpG (500 µg) as adjuvant. Plasma/serum collected at pre vaccination and at multiple time-points post immunization was used to determine anti-IgE antibody titer by ELISA. A: Y-Qb dose response for induction of anti-IgE antibody titer by ELISA. B: Comparison of anti-IgE titer/kinetics with Y-Qb alone (900 µg) or a mix of Y-Qb and P-Qb (450 µg each). C: Plasma collected at 2 weeks post fourth dose in animals immunized with 45 or 900 µg of Qb-Y or 450 µg each of Y-Qb and P-Qb was used to determine antibody avidity by competition ELISA. Significant differences between groups ($p < 0.05$) indicated by asterisk (*).
Immunogenicity of Y-Qb + P-Qb

As shown above, it was not possible to increase anti-IgE antibody titers with antigen dose. Earlier studies in mice had shown the combination of Y-Qb and P-Qb to be superior to Y-Qb alone for anti-IgE antibody titer [36, 37]. In NHP the Y-Qb and P-Qb combination (450 µg each) gave titers that were at least twofold (range 3 to 14-fold) higher than those induced by an equivalent total dose of Y-Qb alone (900 µg), and these differences were significant at almost all time points (p < 0.05, Fig. 1B). Antibody avidity was not significantly different, but there was a trend toward less inter-group variability and higher avidity with the Y-Qb/P-Qb combination compared to Y-Qb alone (Fig. 1C). The competition ELISA assay used to measure avidity in this study has relatively low sensitivity, therefore, better differentiation of avidity may have been observed with a more sensitive assay such as surface plasmon resonance using Biocore (GE Healthcare). However, this was not possible due to limitation of samples volume. Furthermore, the assay interference by varying amounts of endogenous IgE within individual monkey plasma may also have impacted the avidity measurement by competition ELISA.

Plasma from animals dosed with Y-Qb/P-Qb combination using alum and CpG as adjuvants were tested for antibodies specific to Y and P peptides, C3C4, whole IgE, or the Qb VLP carrier. Animals had pre-existing antibody titer ≤ 0.25 K GMT against the Y and P peptides, C3C4, whole IgE, or the Qb VLP and titers developed with similar kinetics post immunization. Although these assays are not strictly comparable due to the use of different coating reagents for the sandwich ELISA, similar antibody titers were detected with IgE and C3C4 (GMT of 71 and 90 K, respectively). Therefore, C3C4 protein was used as coating reagent for all other ELISA data reported in this manuscript. Anti-Y antibody titer (GMT 77K) was also comparable to that for anti-whole IgE whereas the anti-P titers were higher (GMT 262K). As expected, high antibody titers developed against the carrier Qb VLP (GMT 633K) (Fig. 2).

In a separate study, lower doses of Y-Qb + P-Qb (1, 10, or 100 µg each) were tested with alum (250 µg) and CpG (500 µg). Following dosing at 0, 4, and 12 weeks, there was no difference in antibody titer except at 2 weeks after the last dose where 1 µg was inferior (p < 0.05) to 10 or 100 µg (GMT = 39, 147, and 110 K, respectively). Anti-IgE antibodies induced in this study were specific for human IgE and did not cross react with human IgG, IgA, or IgM (Fig. 3). The antigen–antibody dissociation constants (Kd) calculated by ELISA for vaccine-induced antibody against whole human IgE was 36 ± 11.6 nM whereas that for omalizumab was 0.6 nM using the same assay.

Vaccine function: reduction in circulating IgE

Serum IgE levels dropped in some vaccinated animals, with a >50% reduction post fourth dose compared to baseline being achieved in 12.5%, 50%, 50%, and 62.5% of animals in groups receiving 45, 100, 450, or 900 µg Y-Qb + alum/CpG, respectively. The best kinetics and magnitude of IgE reduction was seen with the highest antigen dose tested (900 µg) (Fig. 4).

Although the antibody titer and avidity appeared to be better with the Y-Qb/P-Qb combination, this did not translate into better IgE lowering where Y-Qb/P-Qb at 450 µg each was similar to 450 µg Y-Qb and inferior to 900 µg Y-Qb as sole antigen (Fig. 4).

It is possible that the presence of endogenous anti-IgE antibodies may in theory impact the detection of serum IgE levels using the commercial sandwich ELISA kit employed in this study. However, since the vaccine-induced responses are directed against specific epitopes within the Cε3 domain and the diagnostic anti-IgE reagent is polyclonal, the impact should be minimal. This is confirmed by the fact that in some animals no IgE lowering is detected despite the presence of high levels of anti-IgE antibodies while in other animals different levels of IgE lowering despite similar magnitude of anti-IgE titer. There was no correlation between reduction in circulating IgE and anti-IgE antibody titer or avidity (r² = 0.03), even when analysis was done on a subset of animals with the highest anti-IgE titers (>5 × 10⁴, r² = 0.07).

Effect of adjuvants

At a low antigen dose (20 µg of Y-Qb + P-Qb combination), CpG inclusion with alum in the adjuvant formulation significantly enhanced the anti-IgE antibody response.
compared to alum alone. However, this benefit of CpG was not statistically significant when a high antigen dose (900 μg) was used (Fig. 5A and C, left panel). There was a trend toward greater antibody avidity, with less intra group variability, with alum/CpG compared to alum alone at both antigen doses, albeit with no statistical significance (Fig. 5B and D right panel). Inclusion of CpG with alum had no impact on lowering of circulating IgE (data not shown).

Discussion

This paper combines the findings from a number of different NHP studies carried out during the preclinical development of this anti-IgE vaccine.

All vaccine formulations appeared to be well tolerated which is consistent with observations when the adjuvant and carrier components had been tested previously in NHPs and humans at similar or higher doses. Alhydrogel is widely used in licensed human vaccines. The Qb-VLP has been administered in clinical trials for other indications, for example conjugated to a peptide from angiotensin II for treatment of hypertension (CYT006-AngQb) [44] or conjugated with a nicotine-like hapten for smoking cessation (CYT002-NicQb) [45, 46]. The B-Class CpG ODN used in this study has been tested extensively in NHP during the development of an anti-nicotine vaccine [42, 47, 48], and is pharmacologically similar to CpG adjuvants that have been tested in phase 1 or 2 studies in combination with alum, as in this study, and as a sole adjuvant in phase 3 studies with the Heplisav™ (Dynavax, Berkley, CA) vaccine against hepatitis B [49–54].

Peptide screening studies in mice had identified murine homologues of Y-Qb (mY-Qb) and P-Qb (mP-Qb) as the

![Figure 3. Specificity of vaccine-induced antibodies. Cynomolgus monkeys (n = 8/group) were immunized by IM injection on weeks 0, 4, and 8 with Y-Qb and P-Qb at 450 μg each using alum (800 μg) and CpG (500 μg) as adjuvant. Plasma/serum collected at 10 weeks was tested for specificity of vaccine-induced antibody for binding to human IgE by competition ELISA. Omalizumab was used as positive control. Results presented are the % inhibition in IgE binding.](image-url)
best peptide conjugates for induction of strong antibody responses that cross-react with the intact IgE molecule. In mice, both mY-Qb and mP-Qb induced similar anti-IgE responses with the combination being superior to either peptide conjugate alone. However, mY-Qb was superior to mP-Qb in lowering serum IgE [36]. Since mP-Qb performed relatively poorly on its own in mice, it was not tested as a sole antigen in this study. In NHP immunized with the two human peptide sequence conjugates together, anti-P peptide antibody titers were higher than those against anti-Y peptide, anti-human C3C4, or anti-whole human IgE, which were all similar. This suggests that the P peptide is a good immunogen but anti-P antibodies are less cross-reactive to intact IgE than anti-Y antibodies. Similar to that seen in mice, the Y-Qb and P-Qb combined vaccine gave higher anti-IgE antibody titers than the same total dose of Y-Qb alone. The anti-IgE antibodies induced by the peptide conjugates were capable of recognizing both human and
cynomolgus monkey IgE as shown by similar magnitude and kinetics of anti-human C3C4 and anti-monkey C2C3 antibody titers.

There was a mixed antigen dose effect on immunogenicity in NHP. For anti-IgE antibody titers, the antigen dose response was absent or small. For example, with Y-Qb alone, there was no evidence of an antigen dose response from 45 to 900 μg for titers of anti-IgE Ab. With Y-Qb and P-Qb combined, Ab responses were weaker with very low doses of the combination vaccine (2 μg total) compared to higher doses (20 or 200 μg) for at least some time points. An antigen dose effect was also not evident for antibody avidity. Similarly, in mice a weak dose response was seen with mY-Qb/mP-Qb combination at lower antigen dose levels [36].

All vaccine formulations were adjuvanted since earlier studies in mice and dogs showed very poor immunogenicity for antigen conjugates alone (Huber et al. & Hedlund et al.; manuscripts in preparation). Most groups received both alum and CpG, but results with alum alone were not inferior to those with alum/CpG except at the lowest antigen dose, indicating a lack of CpG effect once a certain dose of antigen is used. It has been well-established with a wide variety of antigens, but not including Qb-VLP conjugates, that alum/CpG significantly enhances antibody responses over alum alone, including in humans studies [50, 55–57]. However, the general lack of adjuvant effect of CpG with Qb-VLP conjugates was not unexpected due to overlapping adjuvant mechanism; the Qb-VLP contains RNA that can activate immune cells via Toll-like receptor (TLR) 7 and TLR8 which use the same MyD88-dependent pathways as CpG, which binds to TLR9 [58]. We have also previously demonstrated a lack of synergy between R848 (TLR7 agonist in mice) and CpG as adjuvants with hepatitis B surface antigen in mice [59]. Downregulation of innate immune responses following in vitro stimulation of human plasmacytoid dendritic cells and B lymphocytes by multiple closely related TLRs (TLR3, 7, 8, and 9) has been reported [60, 61]. This is likely an evolutionary adaptation by the host to prevent overstimulation of the innate immune response.

Some animals had pre-existing anti-IgE antibodies, which did not appear to impact the response to the vaccine. The presence of auto anti-IgE antibodies is well-established in humans, and have been shown to cause modest (<50%) inhibition of in vitro IgE binding to high affinity receptors using a FcεRI-expressing cell-line, as well as to low affinity CD23 receptors on B cells, suggesting possible anti-allergic and pro-allergic effects, respectively [62, 63]. Vaccine-induced anti-IgE antibodies should augment those binding to FcεRI, leading to a better anti-allergic effect.

The vaccine-induced anti-IgE antibodies resulted in significant lowering of serum IgE levels in many of the animals, with some animals achieving as much as 80% lower IgE compared to baseline. Despite the lack of antigen dose...
effect on antibody titer and avidity, there was a clear trend for better functional responses (IgE lowering in blood) with higher antigen doses, suggesting that the assays for titer and avidity are not adequate predictors of anti-IgE vaccine function. However, despite an increase in the overall antibody titer, addition of P-Qb with Y-Qb did not appear to improve the functionality of the antibody over what was seen with Y-Qb alone at same dose. This may be reflective of the poor quality of anti-P antibodies; likely due to conformational restrictions of the epitopes within the P peptide. Various studies have illustrated the benefits associated with introducing conformational constraints such as disulphide constrained loops to enhance affinity of peptide vaccines [28, 64]. Several such modifications were evaluated for both Y and P peptide conjugates to improve the cross-reactive anti-IgE responses induced by the P peptide but no improved cross-reactivity was found (data not shown).

In clinical studies, adequate dosing of omalizumab has been shown to reduce serum free IgE levels by more than 95% in the majority of patients [17]. Baseline levels of IgE seen in the cynomolgus monkeys are higher than typically seen in humans, even atopic humans [65, 66], therefore, it is challenging to compare the degree of reduction of circulating IgE in humans following omalizumab treatment to that seen in NHP following anti-IgE vaccination. Furthermore, studies have shown that omalizumab has to be given at much higher doses in cynomolgus monkeys than in humans to achieve noticeable levels of free IgE suppression [67].

Predicted free IgE levels in asthmatic patients treated with omalizumab were correlated with reported clinical outcomes and a target level of 14 ng/mL was selected to achieve desired clinical benefit, with clear loss of clinical control above ~30 ng/mL [68]. This is an extremely low level of free IgE and one that may be difficult to achieve with a vaccine. Also, unlike omalizumab, which is delivered as a bolus subcutaneous injection; a vaccine will induce a gradual rise in polyclonal anti-IgE antibodies with a different kinetics for antibody and IgE-antibody complex formation to omalizumab. Furthermore, a vaccine-induced polyclonal anti-IgE antibody response will also differ in a number of other ways to administering high dose of a single high affinity monoclonal antibody such as the antibody isotypes, avidity, precise specificity, glycosylation patterns, etc. Vaccine-induced antibodies may also have different functional activities. For example, some anti-IgE antibodies that can recognize epitopes on membrane bound IgE expressed by IgE class switched B-cells have been shown to induce tolerance or apoptosis in IgE secreting B-cells [69], and thereby reduce IgE production. In fact, the murine mimetic of the vaccine described herein also appears to reduce IgE through the loss of IgE-producing B cells (Fraser et al., manuscript in preparation). In the current study, a number of animals showed sustained reduction in circulating IgE (>50%) compared to baseline at 14 weeks after the second immunization despite waning of antibody titers to levels seen after the priming dose when IgE was not reduced as much. Although we did not directly measure the impact of vaccine-induced antibodies on membrane IgE expressing B cells, this sustained reduction of circulating IgE may be indicative of loss of IgE production due to elimination of IgE-producing B cells. In clinical studies with quinlizumab (Genentech), a monoclonal Ab targeting the M1’ region of IgE bound to B cells, IgE was reduced only about 25%, presumably due to the elimination of short-lived but not long-lived IgE-producing plasma cells [70].

Although it was beyond the scope of the current study to evaluate therapeutic efficacy of the vaccine-induced antibodies in monkeys, this was evaluated using mouse and dog mimetics. With mouse prophylactic and therapeutic allergy models and in dog hypersensitive to house dust mites, mimetic vaccines to the human anti-IgE vaccine showed clear symptomatic benefit despite serum IgE levels being reduced less than 90% [36, 39].

Omalizumab binds with high affinity to free IgE, preventing its binding to the FcεRI receptor and while free IgE is drastically reduced, total IgE is greatly increased. Such an increase in total IgE was not detected with the vaccine described here in and pre-clinical data in mice suggest that the anti-IgE antibodies do not prevent IgE from binding to its receptor, but rather there is an increased clearance rate of IgE with reductions of both free and total IgE [36, 37].

In summary, a novel peptide conjugate anti-IgE vaccine was tested in NHP and elicited anti-IgE antibodies that, at least in some animals, could bring about substantial IgE lowering after 3 or 4 vaccine doses. Although the degree of IgE lowering in NHP is less than that seen with omalizumab in humans, the differences in species and potential mechanism of action make it hard to predict how this would translate into humans. Therefore, a decision was made to advance this anti-IgE vaccine into human clinical testing.

Acknowledgments

All authors were Pfizer employees when the study was conducted. We are grateful to Adele Desjardins, Audrey Lavoie, Kathleen Sullivan, and Daisy Yuill for excellent technical assistance. We are also grateful to Brian M. Matthews, David Stead, and Paul Wright for their assistance in generating a number of key reagents that were used in this study.
Conflict of Interest

None declared.

References

1. World Health Organization. 2007. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach.
2. Mannino, D. M., D. M. Homa, L. J. Akinbami, J. E. Moorman, C. Gwynn, and S. C. Redd. 2002. Surveillance for asthma—United States, 1980–1999. MMWR Surveillance Summ 51:1–13.
3. D’Amato, G., S. T. Holgate, R. Pawankar, D. K. Ledford, L. Cecchi, M. Al-Ahmad, F. Al-Enezi, S. Al-Muhsen, I. Ansotegui, C. E. Baena-Cagnani, et al. 2015. Meteorological conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the World Allergy Organization. World Allergy Organ J 8:25.
4. Patel, M. R., H. L. Leo, A. P. Baptist, Y. Cao, and R. W. Brown. 2015. Asthma outcomes in children and adolescents with multiple morbidities: findings from the National Health Interview Survey. J Allergy Clin Immunol 135:1444–1449.
5. Ciprandi, G., G. L. Marseglia, R. Castagnoli, C. Valsecchi, C. Tagliacarne, S. Caimmi, and A. Licari. 2015. From IgE to clinical trials of allergic rhinitis. Expert Rev Clin Immunol 1–13.
6. Pate, M. B., J. K. Smith, D. S. Chi, and G. Krishnaswamy. 2010. Regulation and dysregulation of immunoglobulin E: a molecular and clinical perspective. Clin Mol Allergy 8:3.
7. Wu, L. C., and A. A. Zarrin. 2014. The production and regulation of IgE by the immune system. Nat Rev Immunol 14:247–259.
8. Broide, D. H. 2001. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 108:S65–S71.
9. Busse, W. W., J. Corren, B. Q. Lanier, M. McAlary, A. Fowler-Taylor, G. D. Cioppa, A. A. van, and N. Gupta. 2001. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184–190.
10. D’Amato, G., A. Stanziola, A. Sanduzzi, G. Liccardi, A. Salzillo, C. Vitale, A. Molino, A. Vatrella, and M. D’Amato. 2014. Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review. Multidiscip Respir Med 9:23.
11. Holgate, S., T. Casale, S. Wenzel, J. Bousquet, Y. Deniz, and C. Reisner. 2005. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115:459–465.
12. Saini, S. S., C. Bindslev-Jensen, M. Maurer, J. J. Grob, B. E.bulbul, M. S. Bradley, J. Canvin, A. Rahmaoui, P. Georgiou, O. Alpan, et al. 2015. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 135:67–75.
13. Zuberbier, T., and M. Maurer. 2015. Omalizumab for the treatment of chronic urticaria. Expert Rev Clin Immunol 11:171–180.
14. Vashisht, P., and T. Casale. 2013. Omalizumab for treatment of allergic rhinitis. Expert Opin Biol Ther 13:933–945.
15. Stokes, J. R., and T. B. Casale. 2015. The use of anti-IgE therapy beyond allergic asthma. J Allergy Clin Immunol Pract 3:162–166.
16. El-Qutob, D. 2015. Off-label uses of omalizumab. Clin Rev Allergy Immunol 50:84–96.
17. Busse, W. W. 2001. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 164: S12–S17.
18. Incorvaia, C., M. Mauro, G. G. Riario-Sforza, F. Frati, F. Tarantini, and M. Caserini. 2008. Current and future applications of the anti-IgE antibody omalizumab. Biologics 2:67–73.
19. Humbert, M., W. Busse, N. A. Hanania, P. J. Lowe, J. Canvin, V. J. Erpenbeck, and S. Holgate. 2014. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2:525–536.
20. Wu, A. C., A. D. Paltiel, K. M. Kuntz, S. T. Weiss, and A. L. Fuhlbrigge. 2007. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 120:1146–1152.
21. Corren, J., T. B. Casale, B. Lanier, R. Buhl, S. Holgate, and P. Jimenez. 2009. Safety and tolerability of omalizumab. Clin Exp Allergy 39:788–797.
22. Sussman, G., J. Hebert, C. Barron, J. Bian, R. M. Caron-Guay, S. Laflamme, and S. Stern. 2014. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 112:170–174.
23. Hellman, L. 2008. Therapeutic vaccines against IgE-mediated allergies. Expert Rev Vaccines 7:193–208.
24. Peng, Z. 2009. Vaccines targeting IgE in the treatment of asthma and allergy. Hum Vaccin 5:302–309.
25. Helm, B., D. Kebo, D. Vercelli, M. M. Glovsky, H. Gould, K. Ishizaka, R. Geha, and T. Ishizaka. 1989. Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human epsilon-chain fragment of 76 amino acids. Proc Natl Acad Sci USA 86:9465–9469.
26. Hellman, L. 1994. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur J Immunol 24:415–420.
27. Purcell, A. W., J. McCluskey, and J. Rossjohn. 2007. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6:404–414.
28. Li, W., M. D. Joshi, S. Singhania, K. H. Ramsey, and A. K. Murthy. 2014. Peptide vaccine: progress and challenges. Vaccines (Basel) 2:515–536.

© 2016 Pfizer Inc. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
29. Vernersson, M., A. Ledin, J. Johansson, and L. Hellman. 2002. Generation of therapeutic antibody responses against IgE through vaccination. FASEB J 16:875–877.
30. Johansson, J., and L. Hellman. 2007. Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine. Vaccine 25:1676–1682.
31. Chen, S. S., T. Barankiewicz, Y. M. Yang, M. Zanetti, and P. Hill. 2008. Protection of IgE-mediated allergic sensitization by active immunization with IgE loops constrained in GFP protein scaffold. J Immunol Methods 333:10–23.
32. Stanworth, D. R., V. M. Jones, I. V. Lewin, and S. Nayyar. 1990. Allergy treatment with a peptide vaccine. Lancet 336:1279–1281.
33. Peng, Z., Q. Liu, Q. Wang, E. Rector, Y. Ma, and R. Warrington. 2007. Novel IgE peptide-based vaccine prevents the increase of IgE and down-regulates elevated IgE in rodents. Clin Exp Allergy 37:1040–1048.
34. Wang, C. Y., A. M. Walfeld, X. Fang, B. Hammerberg, J. Ye, M. L. Li, F. Shen, M. Shen, V. Alexander, and D. W. MacGlashan. 2003. Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine 21:1580–1590.
35. Ledin, A., K. Bergvall, N. S. Hillbertz, H. Hansson, G. Andersson, A. Hedhammar, and L. Hellman. 2006. Generation of therapeutic antibody responses against IgE in dogs, an animal species with exceptionally high plasma IgE levels. Vaccine 24:66–74.
36. Champion B. R., D. R. Stead, and P. Wright. 2011. IGE CH3 Peptide Vaccine. [US Patent 8722053].
37. Champion B. R., A. Kjerrstrom, D. Hammond, J. R. Merson, G. Chikh, and P. Saudan. 2010. Development of a VLP-peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies. 4th Global Vaccine Congress.
38. Morsey M. A., M. G. Sheppard, and D. W. Wheeler. 2012. Anti-IgE Vaccines. [United States Patent 8273356].
39. Tsukui T. 2015. IgE peptide vaccine. United States Patent Application 2015023550.
40. Clark, D., F. Shiota, C. Forte, P. Narayanan, D. T. Mytych, and M. B. Hock. 2013. Biomarkers for non-human primate type-I hypersensitivity: antigen-specific immunoglobulin E assays. J Immunol Methods 392:29–37.
41. Vollmer, J., R. Weeratna, P. Payette, M. Jurk, C. Schetter, M. Laucht, T. Wader, S. Tkul, M. Liu, H. L. Davis, et al. 2004. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34:251–262.
42. McCluskie, M. J., D. C. Pryde, D. P. Gervais, D. R. Stead, N. Zhang, M. Benoit, K. Robertson, I. J. Kim, T. Tharmanathan, J. R. Merson, and H. L. Davis. 2013. Enhancing immunogenicity of a 3’aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Int Immunopharmacol 16:50–56.
43. Harris, S. L., H. Tsao, L. Ashton, D. Goldblatt, and P. Fernsten. 2007. Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays. Clin Vaccine Immunol 14:397–403.
44. Maurer, P., and M. F. Bachmann. 2010. Immunization against antigens for the treatment of hypertension. Clin Immunol 134:89–95.
45. Cornuz, J., S. Zwahlen, W. F. Jungi, J. Osterwalder, K. Klingler, G. van Melle, Y. Bangala, I. Guessous, P. Muller J. Willers, et al. 2008. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 3:e2547.
46. Estelris, L., J. O. Hannestad, E. Perkins, F. Bois, D. C. D’Souza, R. F. Tyndale, J. P. Seibyl, D. M. Hatsuikami, K. P. Cosgrove, and S. S. O’Malley. 2013. Effect of a nicotine vaccine on nicotine binding to beta2-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am J Psychiatry 170:399–407.
47. McCluskie, M. J., J. Thorn, P. R. Mehelic, P. Kolhe, K. Bhattacharya, J. I. Finneman, D. R. Stead, M. B. Piatchek, N. Zhang, G. Chikh, et al. 2015. Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates. Int Immunopharmacol 25:518–527.
48. McCluskie, M. J., J. Thorn, D. P. Gervais, D. R. Stead, N. Zhang, M. Benoit, J. Cartier, I. J. Kim, K. Bhattacharya, J. I. Finneman, et al. 2015. Anti-nicotine vaccines: comparison of adjuvanted CRM and QB-VLP conjugate formulations for immunogenicity and function in non-human primates. Int Immunopharmacol 29:663–671.
49. Cooper, C. L., H. L. Davis, M. L. Morris, S. M. Efier, A. M. Krieg, Y. Li, C. L. Martin, M. J. Al Adhami, Y. Khalqi, I. Seguin, et al. 2004. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22:3136–3143.
50. Cooper, C. L., H. L. Davis, M. L. Morris, S. M. Efier, M. A. Adhami, A. M. Krieg, D. W. Cameron, and J. Heathcote. 2004. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to engerix-B((R)) HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24:693–701.
51. Cooper, C. L., H. L. Davis, J. B. Angel, M. L. Morris, S. M. Efier, I. Seguin, A. M. Krieg, and D. W. Cameron. 2005. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. Aids 19:1473–1479.
52. Cooper, C. L., J. B. Angel, I. Seguin, H. L. Davis, and D. W. Cameron. 2008. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 46:1310–1314.
53. Halperin, S. A., S. Dobson, S. McNeil, J. M. Langley, B. Smith, R. McCall-Sani, D. Levitt, G. V. Nest, D. Gennevois, and J. J.
Eiden. 2006. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 24:20–26.

54. Eng, N. F., N. Bhardwaj, R. Mulligan, and F. Diaz-Mitoma. 2013. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV review. Hum Vaccin Immunother 9:1661–1672.

55. Duncan, C. J., S. H. Sheehy, K. J. Ewer, A. D. Douglas, K. A. Collins, F. D. Halstead, S. C. Elias, P. J. Lilie, K. Rausch, J. Aebig, et al. 2011. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS ONE 6: e22271.

56. Ellis, R. D., G. E. Mullen, M. Pierce, L. B. Martin, K. Miura, M. P. Fay, C. A. Long, D. Shaffer, A. Saul, L. H. Miller, et al. 2009. A phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine 27:4104–4109.

57. Rynkiewicz, D., M. Rathkopf, I. Sim, A. T. Waytes, R. J. Hopkins, L. Giri, D. DeMuria, J. Ransom, J. Quinn, G. S. Nabors, et al. 2011. Marked enhancement of the immune response to BioThrax(R) (anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 29:6313–6320.

58. Akira, S., and H. Hemmi. 2003. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 85:85–95.

59. Weeratna, R. D., S. R. Makinen, M. J. McCluskie, and H. L. Davis. 2005. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 23:5263–5270.

60. Booth, J. S., J. J. Buza, A. Potter, L. A. Babiuk, and G. K. Mutwiri. 2010. Co-stimulation with TLR7/8 and TLR9 agonists induce down-regulation of innate immune responses in sheep blood mononuclear and B cells. Dev Comp Immunol 34:572–578.

61. Marshall, J. D., D. S. Hecke, M. L. Gesner, B. Livingston, and G. Van Nist. 2007. Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand. J Leukoc Biol 82:497–508.

62. Smith, S. J., N. S. Jones, and F. Shakib. 1995. Circulating IgG autoanti-IgE antibodies in atopic patients block the binding of IgE to its low affinity receptor (CD23). Clin Mol Pathol 48: M342–M346.

63. Smith, S. J., A. Galvin, I. Hall, and F. Shakib. 1995. Circulating human IgG autoanti-IgE antibodies in asthma patients block the binding of IgE to its high affinity receptor. Clin Mol Pathol 48:M148–M152.

64. Dakappagari, N. K., K. D. Lute, S. Rawale, J. T. Steele, S. D. Allen, G. Phillips, R. T. Reilly, and P. T. Kaumaya. 2005. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J Biol Chem 280:54–63.

65. Borish, L. B., Chipp, Y. Deniz, S. Gujrathi, B. Zheng, and C. M. Dolan. 2005. Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 95:247–253.

66. Wittig, H. J., J. Belloit, I. De F, and G. Royal. 1980. Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. J Allergy Clin Immunol 66:305–313.

67. Mortensen, D. L., S. Prabhu, E. G. Stefanich, S. Kadkhodayan-Fischer, T. R. Gelzeleichter, D. Baker, J. Jiang, K. Wallace, S. Iyer, P. J. Fielder, et al. 2012. Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. MAbs 4:724–731.

68. Lowe, P. J., S. Tannenbaum, A. Gautier, and P. Jimenez. 2009. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 68:61–76.

69. Feichtner, S., D. Infuhr, G. Achatz-Straussberger, D. Schmid, A. Karnowski, M. Lamers, C. Rhyner, R. Cramer, and G. Achatz. 2008. Targeting the extracellular membrane-proximal domain of membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. J Immunol 180:5499–5505.

70. Gauvreau, G. M., J. M. Harris, L. P. Boulet, H. Scheerens, J. M. Fitzgerald, W. S. Putnam, D. W. Cockcroft, B. E. Davis, R. Leigh, Y. Zheng, et al. 2014. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med 6:243ra85.